Genethera Inc (GTHR) Financial Statements (2024 and earlier)
Company Profile
Business Address |
3051 W 105TH AVENUE WESTMINSTER, CO 80031 |
State of Incorp. | NV |
Fiscal Year End | December 31 |
Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Prepaid expense | 1,022 | 1,022 | 1,022 | 1,022 | |||||
Total current assets: | 1,022 | 1,022 | 1,022 | 1,022 | |||||
Noncurrent Assets | |||||||||
Property, plant and equipment | 2,640 | 3,960 | 5,280 | 6,600 | 7,920 | 9,240 | |||
Total noncurrent assets: | 2,640 | 3,960 | 5,280 | 6,600 | 7,920 | 9,240 | |||
TOTAL ASSETS: | 2,640 | 3,960 | 6,302 | 7,622 | 8,942 | 10,262 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 13,803,266 | 7,494,530 | 7,367,721 | 7,253,935 | 7,135,791 | 7,017,088 | |||
Employee-related liabilities | 6,191,623 | ✕ | |||||||
Accounts payable | 91,070 | 91,070 | 81,070 | 81,070 | 81,070 | 81,070 | |||
Accrued liabilities | 7,520,573 | 7,403,460 | 7,286,651 | 7,172,865 | 7,054,721 | 6,936,018 | |||
Debt | 25,800 | 25,800 | 25,800 | 25,800 | 25,800 | 25,800 | |||
Due to related parties | 716,569 | 724,562 | 720,969 | 720,969 | 730,468 | 744,119 | |||
Other undisclosed current liabilities | 54,500 | ||||||||
Total current liabilities: | 14,545,635 | 8,244,892 | 8,114,490 | 8,000,704 | 7,892,059 | 7,841,507 | |||
Noncurrent Liabilities | |||||||||
Other undisclosed liabilities | (6,127,123) | 64,500 | 64,500 | 64,000 | 54,500 | ||||
Total liabilities: | 8,418,512 | 8,309,392 | 8,178,990 | 8,064,704 | 7,946,559 | 7,841,507 | |||
Equity | |||||||||
Equity, attributable to parent, including: | (8,415,871) | (8,305,432) | (8,172,688) | (8,051,082) | (7,937,617) | (7,831,245) | |||
Common stock | 35,333 | 34,083 | 34,083 | 30,971 | 28,571 | 25,571 | |||
Additional paid in capital | 24,021,313 | 23,985,064 | 23,985,064 | 23,834,776 | 23,706,776 | 23,529,776 | |||
Accumulated deficit | (32,552,129) | (32,404,191) | (32,271,446) | (31,996,440) | (31,752,575) | (31,466,202) | |||
Other undisclosed equity, attributable to parent | 79,612 | 79,612 | 79,611 | 79,611 | 79,611 | 79,610 | |||
Other undisclosed equity | (1) | (6,000) | |||||||
Total equity: | (8,415,872) | (8,305,432) | (8,172,688) | (8,057,082) | (7,937,617) | (7,831,245) | |||
TOTAL LIABILITIES AND EQUITY: | 2,640 | 3,960 | 6,302 | 7,622 | 8,942 | 10,262 |
Income Statement (P&L) (USD)Annual | Quarterly
9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
---|---|---|---|---|---|---|---|---|
Operating expenses | (147,382) | (132,189) | (277,720) | (242,220) | (284,726) | (204,595) | ||
Other operating income (expense), net (Other Expenses) | 4,938 | (1,646) | ||||||
Other undisclosed operating income (loss) | (4,938) | 1,646 | ||||||
Operating loss: | (147,382) | (132,189) | (277,720) | (242,220) | (284,726) | (204,595) | ||
Nonoperating expense | (556) | (556) | (1,646) | |||||
Interest and debt expense | (556) | (1,646) | ||||||
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 556 | 2,714 | (1,646) | |||||
Loss from continuing operations before equity method investments, income taxes: | (147,938) | (132,745) | (275,006) | (243,866) | (286,372) | (206,241) | ||
Other undisclosed income from continuing operations before income taxes | ||||||||
Loss from continuing operations: | (147,938) | (132,745) | (275,006) | (243,866) | (286,372) | (206,241) | ||
Loss before gain (loss) on sale of properties: | (147,938) | (132,745) | (275,006) | (243,866) | (286,372) | (206,241) | ||
Net loss available to common stockholders, diluted: | (147,938) | (132,745) | (275,006) | (243,866) | (286,372) | (206,241) |
Comprehensive Income (USD)Annual | Quarterly
9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (147,938) | (132,745) | (275,006) | (243,866) | (286,372) | (206,241) | ||
Comprehensive loss, net of tax, attributable to parent: | (147,938) | (132,745) | (275,006) | (243,866) | (286,372) | (206,241) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.